How much did Amyl Therapeutics raise?

Amyl Therapeutics raised $8.9M at Series A, announced 1 September 2026.

Who founded Amyl Therapeutics?

Pierre Vandepapeliere is CEO & Co-founder of Amyl Therapeutics.

What does Amyl Therapeutics do?

Amyl Therapeutics operates in HealthTech and is based in Belgium.

FundedStartupsDaily / HealthTech / Amyl Therapeutics

Amyl Therapeutics raises $8.9M

Amyl Therapeutics announced a Series A round of $8.9M on 1 September 2026. The company operates in HealthTech and is based in Belgium. It was founded by Pierre Vandepapeliere, CEO & Co-founder.

Raised

$8.9M

Stage

Series A

Industry

HealthTech

Country

Belgium

Founder

Pierre Vandepapeliere

CEO & Co-founder, Amyl Therapeutics

LinkedIn profile amyltx.com

Outreach angles

-Vandepapeliere co-founded Amyl Therapeutics with Dr. Florent Gros to build a fusion-protein platform targeting neurodegenerative diseases.
-He serves as both CEO and Chief Medical Officer of the company, drawing on his clinical background to guide its drug development strategy.
-Amyl Therapeutics intends to double its R&D team in Liege and use its new funding to finalize its clinical candidate for GMP manufacturing.